Pharmaceutical

EC conditionally approves Pfizer’s haemophilia B gene therapy

The European Commission has awarded conditional marketing authorisation for Pfizer's DURVEQTIX for haemophilia B treatment.

Jul 28, 2024 - 04:00
EC conditionally approves Pfizer’s haemophilia B gene therapy
The European Commission has awarded conditional marketing authorisation for Pfizer's DURVEQTIX for haemophilia B treatment.
Read the original article

Tags:

Previous Article

AbbVie’s Q2 2024 net earnings drop to $1.37bn

Next Article

Pfizer’s Hemophilia Gene Treatment Reaches Late-Stage Research Target

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AZ to terminate once-daily cotadutide program to focus on weekly GLP-1RA co-agonist

AZ to terminate once-daily cotadutide program to focus ...

Apr 22, 2023

STAT+: Former FDA official lays out how to keep patients safe from risky medical devices

STAT+: Former FDA official lays out how to keep patient...

Oct 2, 2023

STAT+: Government warns Medicare Advantage insurers not to deny care based on AI

STAT+: Government warns Medicare Advantage insurers not...

Feb 7, 2024